[Edaily Reporter Shin Ha-yeon ] Global life care company NUON(123840)announced on the 31st that cumulative sales of its weight management health supplement, “Cissus Pill Diet,” have surpassed 70 million tablets.

According to the company, Cissus Pill Diet recorded cumulative sales of 70 million tablets from its launch in 2019 through June of this year. Cumulative sales of cissus extract—the product’s main ingredient—also exceeded 105.3 billion won.

With the recent spread of obesity treatments “Wegovy” and “Mounjaro,” interest in GLP-1 (glucagon-like peptide-1) has grown, drawing attention to research on related functional ingredients. GLP-1 is known as a hormone secreted in the intestines after food intake that increases satiety and regulates appetite.

NUON explained that the results of a human clinical trial on the effect of Cissus extract—an individually recognized ingredient—on increasing GLP-1 secretion were published in the international academic journal *Medicina*.

The study was a 16-week randomized, double-blind, placebo-controlled human clinical trial involving 248 overweight and obese adults. It confirmed an increase in GLP-1 secretion and a tendency toward DPP-4 activity inhibition in the Cissus extract group. The company added that no serious adverse reactions occurred during the trial, and gastrointestinal discomfort was observed in less than 3% of participants.

A company official stated, “As interest in GLP-1-based therapies such as Wegovy and Mounjaro grows, understanding of the underlying mechanisms is also expanding,” adding, “Research into the physiological effects of plant-derived ingredients associated with GLP-1 is also actively underway.”

The spokesperson continued, “Cissus Fil Diet continues to deliver stable performance in the market, backed by long-term sales data and research findings on its active ingredients,” adding, “We will continue to strengthen the product’s competitiveness based on scientific evidence.”